Related Experiment Video
Updated: Sep 6, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
Published on: February 10, 2011
Anti-MRSA cephalosporins Bristol-Myers Squibb
1Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, London, UK. ajohnson@phls.nhs.uk
Abstract:
BMS is investigating a series of cephalosporins for potential use in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection [274213]. In vitro activity tests resulted in a minimum inhibitory concentration (MIC) of 1 to 8 microg/ml against MRSA 1274213]. A series of C(3) benzoyloxymethyl cephalosporins exhibited in vitro activity against MRSA and methicillin-susceptible Staphylococcus aureus (MSSA), with MIC values ranging from 0.007 to 2 microM, and improved in vivo stability in human plasma [258890].
Related Concept Videos
Rocky Mountain Spotted Fever
Mechanism of Antibiotic Resistance in MRSA
Respiratory Syncytial Virus Disease
Clinical Significance of Antibiotic Resistance

